News ArchivesRead News
New Digital Cognitive Assessment Tool Receives Positive FDA Review
Monday July 31, 2017
Parkinson's News Today - The cognitive science company Cogstate received approval to market a new digital cognitive assessment tool to assist healthcare professionals in measuring cognition in patients ages 6 to 99, either in-clinic or at home. This tool, called the Cognigram, could help measure the progression of Parkinson’s disease and other illnesses.
The Cognigram can now be marketed in the United States after the U.S. Food and Drug Administration (FDA) reviewed the company’s 510(k) submission and found it to meet the necessary requirements established by the FDA’s Center for Devices and Radiological Health.
An individual’s cognition may be affected by mild cognitive impairment (MCI), Alzheimer’s disease, Parkinson’s disease, concussion, head injury, HIV-related dementia, major depressive disorder, and secondary effects of medication or surgery, among others, including psychological states like stress or fatigue.
The Cognigram system is a simple computerized battery of tests based on a card game designed to detect and monitor change in cognitive function over time. The system can be used to assess cognition on a single occasion or cognitive change over periodic assessments, regardless of language, education, and cultural background.
The Cognigram will be made available to U.S. health systems, hospitals, physician practices, elderly care organizations, schools, and sports teams.
“After more than fifteen years of intense efforts in supporting academic research and pharmaceutical clinical trials around the world, Cogstate is excited to enter the U.S. market for cognitive assessment on the front lines of clinical practice,” Frank Cheng, president of Cogstate Healthcare, said in a press release. “We look forward to bringing the proven and widely-published Cognigram technology into the healthcare ecosystem to benefit an exponentially larger pool of patients.”
A 2015 study explored controversies about mild cognitive impairment in Parkinson’s disease (PD-MCI), noting that cognitive impairment in Parkinson’s is increasing.
MCI is a known risk factor for dementia in Parkinson’s, but this process isn’t fully understood. In this study, the authors explored signs of PD-MCI, biomarkers, and how PD-MCI factors into clinical trial design.
The article also explores how PD-MCI definitions have evolved over the years, and how prevention may be incorporated into PD treatment. Today, monitoring PD-MCI is commonly incorporated as a measurement for PD clinical trials.
Titled, “Mild cognitive impairment: an update in Parkinson’s disease and lessons learned from Alzheimer’s disease,” the article was published in Neurodegenerative Disease Management.
Recent NewsJun 18 - Your Weekly News Update for the Week of 6.18.18
Jun 11 - Your Weekly News Update for the Week of 6/11/18
Jun 4 - Your Weekly News Update for the Week of 6/4/18
May 29 - Your Weekly News Update for the Week of 5/28/18
May 21 - Your Weekly News Update for the Week of 5/21/18
May 15 - Your Weekly News Update for the Week of 5/14/18
May 7 - Your Weekly News Updates for the Week of 5/7/18
Apr 30 - Your Weekly News Updates for the Week of 4/30/18
Apr 24 - Parkinson's News Updates for April 24, 2018
Apr 11 - 2 Markers of Parkinson’s Progression May Help Trials in Newly Diagnosed Patients
Apr 10 - Augmented reality app may aid patients with Parkinson’s
Apr 10 - April 10, 2018 News Update
Apr 9 - Study: App accurately tracks Parkinson's disease symptoms
Apr 3 - April 3, 2018 News Update
Mar 27 - March 27, 2018 News Update
Mar 20 - March 20, 2018 News Update
Mar 13 - March 13, 2018 News Update
Mar 6 - March 6, 2018 News Update
Feb 27 - February 27, 2018 News Update
Feb 20 - February 20, 2018 News Update